StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the stock.

Several other research analysts have also recently weighed in on EKSO. Lake Street Capital began coverage on shares of Ekso Bionics in a report on Monday, June 24th. They set a buy rating and a $2.50 price objective for the company. HC Wainwright raised their price target on Ekso Bionics from $9.25 to $10.00 and gave the stock a buy rating in a research note on Tuesday, April 30th.

Ekso Bionics Stock Performance

Shares of Ekso Bionics stock opened at $1.06 on Friday. The stock has a market cap of $19.17 million, a price-to-earnings ratio of -1.09 and a beta of 1.49. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.81 and a quick ratio of 2.11. Ekso Bionics has a 1 year low of $0.62 and a 1 year high of $3.13. The firm’s 50-day moving average is $1.20 and its 200 day moving average is $1.60.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.99 million. Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 95.36%. During the same period last year, the business earned ($0.33) EPS. Sell-side analysts anticipate that Ekso Bionics will post -0.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC lifted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 21.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the quarter. Strategic Wealth Investment Group LLC owned about 0.37% of Ekso Bionics worth $130,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.